UNSPSC 51151633: Dihexyverine

This classification denotes an antispasmotic agent and antimuscarinic agent with the molecular formula C20H35NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J2FQ66RU9W, chemically known as 2-piperidinoethyl (1,1-bicyclohexyl)-1-carboxylate but generally known as dihexyverine, which bears US NIH Compound Identifier 21788. European Medicines Agency schedules dihexyverine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07136MIG. Most nations schedule dihexyverine under HS 29333999 and SITC 51574.

As of Q4 2014, DIHEXYVERINE remains the US FDA Preferred Term for this commodity. Dihexyverine bears US NLM identifiers UMLS ID C0771461 and NCI Concept Code C97978. SMILES: C1CCC(CC1)C2(CCCCC2)C(=O)OCCN3CCCCC3.

UNSPSC 51151633 Dihexyverine is a Commodity code with minimal recent state and local procurement activity directly aligned to its nominal scope. The two most recent opportunities posted under this code—Seminole County's procurement of naloxone and drug deactivation systems, and the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs—do not reflect purchasing of dihexyverine itself. Instead, they signal that the code may be used as a catch-all classification for pharmaceutical procurement activity, particularly substances and delivery mechanisms related to public health initiatives, emergency response, and pharmacy benefit management. State and local issuers using this code appear to include county health departments, state health and human services agencies, and other public health-focused jurisdictions. The work actually being solicited encompasses opioid antagonists (naloxone), drug deactivation systems, and indirect inquiry into direct pharmaceutical contracting models rather than the specific pharmaceutical compound the code nominally names.

Activity is concentrated in Florida and Texas based on recent postings. Seminole County, Florida posted IFB 60459723LAS on June 30, 2026, with a response deadline of July 26, 2023, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford; the contract includes a two-year initial term with a one-year renewal option and requires E-Verify compliance, drug-free workplace certification, and specific insurance coverage. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription programs, framed as a preliminary information-gathering phase before formal RFP development. The code shows no evidence of sustained or high-volume purchasing activity at this tier; state and local procurement under this Commodity designation appears episodic and geographically scattered.